Why Merck is a Top Socially Responsible Dividend Stock (MRK)

Merck & Co Inc (MRK) is a component of the iShares MSCI USA ESG Select ETF (SUSA) and the iShares MSCI KLD 400 Social Index Fund ETF (DSI), with weightings of 0.31% and 0.70% respectively. The company's annualized dividend is $3.24 per share, paid quarterly, with the latest ex-date on 06/16/2025; its dividend history is considered important for assessing the sustainability of future payouts.

Analysis

Merck & Co Inc. (MRK) is highlighted for its socially responsible investment profile, evidenced by its inclusion in the iShares MSCI USA ESG Select ETF (SUSA) with a 0.31% weighting and the iShares MSCI KLD 400 Social Index Fund ETF (DSI) with a 0.70% weighting. The company maintains a shareholder return policy featuring an annualized dividend of $3.24 per share, paid in quarterly installments, with a recent ex-dividend date noted as June 16, 2025. The article explicitly states that studying MRK's historical dividend record is of key importance for assessing the likelihood of future dividend continuity. Operating within the Drugs & Pharmaceuticals sector, Merck is positioned among industry peers such as Eli Lilly (LLY) and Novo-Nordisk AS (NVO). This information underscores MRK's characteristics relevant to investors focused on ESG criteria and consistent income generation, which are integral to its fundamental appeal and capital return strategy within the competitive healthcare landscape.

Key Decisions for Investors

• Investors interested in income generation and ESG alignment should note Merck's current annualized dividend of $3.24 per share, paid quarterly, and its confirmed presence in notable ESG-focused ETFs.
• A thorough examination of Merck's long-term dividend payment history is critical for assessing the sustainability and reliability of future payouts, a point emphasized as being of key importance.
• It may be prudent to evaluate MRK's dividend policy and overall financial health in comparison to its pharmaceutical sector peers like Eli Lilly and Novo-Nordisk, although the provided information does not offer a direct comparative analysis.